← All medicines

Diabetes

Repaglinide

Independent educational summary · Sources checked November 20, 2026

A mealtime insulin-release stimulant for type 2 diabetes.

Profile scope: Repaglinide. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Headache, nasal symptoms, joint discomfort, constipation, nausea, or diarrhea may occur.

Serious risks and warning signs

Low glucose can cause sweating, shakiness, hunger, or dizziness and can progress to seizures or unconsciousness. Meals and interactions affect risk. Do not improvise a response to skipped meals or recurrent low readings.

A question for your healthcare team

What meal and low-glucose instructions should I follow, and which medicines could substantially increase exposure?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.